Edition:
United States

Forward Pharma A/S (FWP.OQ)

FWP.OQ on NASDAQ Stock Exchange Global Select Market

1.18USD
4:00pm EDT
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$1.18
Open
$1.18
Day's High
$1.18
Day's Low
$1.18
Volume
13
Avg. Vol
5,095
52-wk High
$4.42
52-wk Low
$0.71

Latest Key Developments (Source: Significant Developments)

Forward Pharma Provides Update On Decision Of The Federal Circuit In Appeal Of The U.S. Patent Interference
Wednesday, 24 Oct 2018 10:42am EDT 

Oct 24 (Reuters) - Forward Pharma A/S ::FORWARD PHARMA PROVIDES UPDATE ON THE DECISION OF THE FEDERAL CIRCUIT IN ITS APPEAL OF THE U.S. PATENT INTERFERENCE.FORWARD PHARMA A/S - APPEAL OF EUROPEAN EP2801355 PATENT OPPOSITION CONTINUES.FORWARD PHARMA A/S - FORWARD EXPECTS TO REDUCE OPERATING EXPENSES TO MATCH CURRENT SITUATION.FORWARD PHARMA - U.S. COURT OF APPEALS FOR FEDERAL CIRCUIT AFFIRMED DECISION OF PATENT TRIAL AND APPEAL BOARD IN U.S. PATENT INTERFERENCE PROCEEDING.FORWARD PHARMA - FEDERAL CIRCUIT AFFIRMED PTAB DECISION IN INTERFERENCE PROCEEDING BETWEEN CO'S U.S. '871 PATENT APPLICATION & AN ISSUED BIOGEN PATENT.  Full Article

Forward Pharma Reports Financial Results From First Six Months Of 2018
Wednesday, 19 Sep 2018 04:20pm EDT 

Sept 19 (Reuters) - Forward Pharma A/S ::FORWARD PHARMA REPORTS FINANCIAL AND OPERATIONAL RESULTS FROM THE FIRST SIX MONTHS OF 2018.  Full Article

Mark Lampert Reports 11.3 Percent Passive Stake In Forward Pharma A/S
Wednesday, 3 Jan 2018 06:09am EST 

Jan 3 (Reuters) - Forward Pharma A/S ::MARK LAMPERT REPORTS 11.3 PERCENT PASSIVE STAKE IN FORWARD PHARMA A/S AS OF DECEMBER 22 .  Full Article

Forward Pharma Files Further Written Submissions In European Opposition Proceeding For EP2801355 Patent
Wednesday, 29 Nov 2017 04:30pm EST 

Nov 29 (Reuters) - Forward Pharma A/S ::FORWARD PHARMA FILES FURTHER WRITTEN SUBMISSIONS IN THE EUROPEAN OPPOSITION PROCEEDING FOR THE EP2801355 PATENT IN PREPARATION FOR THE ORAL HEARING IN JANUARY 2018.FORWARD PHARMA A/S - FILING OF FURTHER WRITTEN SUBMISSIONS IN EUROPEAN OPPOSITION PROCEEDING FOR EP2801355 PATENT WITH EPO.FORWARD PHARMA A/S - FILING WILL BECOME PUBLICLY AVAILABLE VIA EUROPEAN PATENT REGISTER.FORWARD PHARMA A/S - AN ORAL HEARING IS CURRENTLY SCHEDULED FOR JANUARY 29-30, 2018.FORWARD PHARMA A/S - POSSIBILITY TO APPEAL DECISION OF OPPOSITION DIVISION TO TECHNICAL BOARD OF APPEAL.  Full Article

Forward Pharma announces completion of corporate restructuring plan
Wednesday, 22 Nov 2017 04:30pm EST 

Nov 22 (Reuters) - Forward Pharma A/S :Forward Pharma announces completion of corporate restructuring plan.  Full Article

Forward pharma says filing in U.S. Court to appeal PTAB decision​
Tuesday, 5 Sep 2017 05:00pm EDT 

Sept 5 (Reuters) - Biogen Inc :Forward pharma a/s says filing in a u.s. Court of opening brief for appeal of a ptab decision​.Forward pharma - ‍the ptab decision ended interference proceeding between forward's 11/576,871 patent application and an issued biogen patent​.Forward pharma - ‍after biogen files its responsive brief, currently due oct 16, 2017, forward is allowed a reply brief, currently due october 30, 2017​.Forward pharma a/s - ‍an oral argument is expected to be held before the federal circuit in late 2017 or early 2018​.  Full Article

Forward Pharma board approves capital reduction
Friday, 1 Sep 2017 07:00am EDT 

Sept 1 (Reuters) - Forward Pharma A/S :Forward Pharma board of directors approves capital reduction and returns EUR 917.7 million to shareholders.Forward Pharma A/S - the company effected the capital reduction with a distribution of proceeds to holders of ordinary shares‍​.Forward Pharma A/S - ‍record date for holders of ADS to receive a ratable portion of capital reduction will be September 7, 2017​.Forward Pharma A/S - ‍ADSs are expected to begin trading "ex-dividend" on September 12, 2017​.  Full Article

Forward Pharma obtains shareholder approval of capital reduction
Wednesday, 2 Aug 2017 04:45pm EDT 

Aug 2 (Reuters) - Forward Pharma A/S :Forward Pharma obtains shareholder approval of the planned capital reduction at the extraordinary general meeting.Forward Pharma A/S - got ruling from Danish tax authorities covering holders of ordinary shares and holders of Forward's American depositary shares​.Forward Pharma A/S - ‍based on ruling, company will not be withholding any part of proceeds from capital reduction for Danish tax​.Forward Pharma A/S - ‍majority of votes cast at shareholder meeting approved plans to return EUR 917.7 million to shareholders through a capital reduction​.  Full Article

Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders
Tuesday, 18 Jul 2017 08:05am EDT 

July 18 (Reuters) - Forward Pharma A/S ::Forward Pharma announces planned distribution of EUR 19.45 per share to shareholders.Forward Pharma A/S - plans to return EUR 19.45 per share amounting to a total of EUR 917.7 million to its shareholders through a capital reduction.Forward Pharma A/S - plans to complete capital reduction in early September 2017.Forward Pharma - decision is based on careful evaluation of most appropriate capital allocation strategy after receipt of non-refundable $1.25 billion cash fee from Biogen.Forward Pharma - capital reduction aligns amount of working capital with adjusted business activities following settlement and license agreement with Biogen.Forward Pharma A/S - shareholders representing over two-thirds of voting share capital have irrevocably agreed to vote in favor of capital reduction.  Full Article